Table I Features of Children with Problematic Wheeze/Asthma Compared According to VHI % Dispersion Table I Features of Children with Problematic Wheeze/Asthma Compared According to VHI % Dispersion Table I Features of Children with Problematic Wheeze/Asthma Compared According to VHI % Dispersion Table I Features of Children with Problematic Wheeze/Asthma Compared According to VHI % Dispersion Table I Features of Children with Problematic Wheeze/Asthma Compared According to VHI % Dispersion
Mild VH 25th %ile n=15 Moderate VH 25th-75th %ile n=30 Severe VH 75th %ile n=15 Total n=60
Age (years) α 10.6 ± 3.5 9.1 ± 3.9 11.1 ± 4.3 9.9 ± 3.9
Asthma Duration (years) 7.4 ± 2.8 6.1 ± 4.4 8.3 ± 3.9 6.9 ± 4.0
Male sex n (%) ** 11 (73) 18 (60) 9 (60) 38 (63)
Non-white race n (%) 3 (20) 16 (53) 11 (73) Ϯ 30 (50)
Body Mass Index (kg/m2) 20.2 ± 3.3 21.3 ± 6.4 21.6 ± 6.5 21.1 ± 5.8
BMI % predicted 75 ± 18 74 ± 27 64 ± 40 72 ± 29
Obese n (%) 3 (20) 12 (40) 6 (40) 21 (35)
ACT/cACT 18 ± 4 15 ± 4 14 ± 4 16 ± 5
Hospital Admissions 0 ± 1 0 ± 2 1 ± 5 µ 1 ± 2
ICU Admissions 0 (0-1) 0 (0-2) 0 (0-6) ϴ 0 (0-6)
# Controller Meds 2 ± 1 2 ± 1 4.0 ± 2 Ɣ 3 ± 1
Daily ICS Dose 400 ± 640 460 ± 520 800 ± 460 640 ± 480
Pre-BD FEV­1­ % 100 ± 12 93 ± 17 80 ± 28 β 91 ± 20
Post-BD FEV­1­ % 111 ± 10 101 ± 21 90 ± 27 Ω 99 ± 23
∆ FEV­1­ % post-BD 15 ± 24 11 ± 10 22 ± 12 ¥ 15 ± 15
Pre-BD FVC % 108 ± 10 103 ± 14 97 ± 25 103 ± 17
Post-BD FVC % 117 ± 2 106 ± 16 102 ± 27 107 ± 20
∆ FVC % post-BD 2 ± 6 2 ± 5 8 ± 9 Ω 4 ± 7
Pre-BD FEV­1­/FVC % 94 ± 11 89 ± 11 83 ± 12 ϴ 89 ± 12
Post-BD FEV­1­/FVC % 96 ± 9 95 ± 11 90 ± 13 93 ± 11
Pre-BD FEF­25-75­ % 89 ± 26 76 ± 34 55 ± 33 β 74 ± 34
Post-BD FEF25-75 % 91 ± 33 94 ± 43 61 ± 35 Ω 83 ± 41
Geometric Mean Total IgE (IU/ml) 174 (24-4804) 151 (1-3638) 385 κ (47-2047) 197 (1-4804)
# + specific IgE tests 3 ± 7 4 ± 11 6 ± 8 5 ± 8
Highly Sensitized n (%) 7 (47) 17 (57) 12 (80) 36 (60)
Absolute Blood Eosinophils (cells/µl) α 220 ± 180 285 ± 440 620 ± 660 λ 447 ± 403
Blood Eosinophilia (≥ 300 cells/µl) n (%) 3 (20) 14 (47) 13 (87) †† 30 (50)
Expired NO (ppb) 22 ± 11 19 ± 11 36 ± 18 π 23 ± 14
α mean ± SD; ** column %; Ϯ p = .006, ∆ p = .09 compared to mild VH; u p =.06; ϴ p = .04 compared to mild VH; Ɣ p = .02; β p = .02 compared to mild VH; Ω p = .08 compared to mild; ¥ p = .01 compared to moderate VH; κ p = .08 compared to moderate VH. λ p = .001 compared to mild and moderate VH. ϮϮ p = .001. π p = .03 compared to moderate VH. α mean ± SD; ** column %; Ϯ p = .006, ∆ p = .09 compared to mild VH; u p =.06; ϴ p = .04 compared to mild VH; Ɣ p = .02; β p = .02 compared to mild VH; Ω p = .08 compared to mild; ¥ p = .01 compared to moderate VH; κ p = .08 compared to moderate VH. λ p = .001 compared to mild and moderate VH. ϮϮ p = .001. π p = .03 compared to moderate VH. α mean ± SD; ** column %; Ϯ p = .006, ∆ p = .09 compared to mild VH; u p =.06; ϴ p = .04 compared to mild VH; Ɣ p = .02; β p = .02 compared to mild VH; Ω p = .08 compared to mild; ¥ p = .01 compared to moderate VH; κ p = .08 compared to moderate VH. λ p = .001 compared to mild and moderate VH. ϮϮ p = .001. π p = .03 compared to moderate VH. α mean ± SD; ** column %; Ϯ p = .006, ∆ p = .09 compared to mild VH; u p =.06; ϴ p = .04 compared to mild VH; Ɣ p = .02; β p = .02 compared to mild VH; Ω p = .08 compared to mild; ¥ p = .01 compared to moderate VH; κ p = .08 compared to moderate VH. λ p = .001 compared to mild and moderate VH. ϮϮ p = .001. π p = .03 compared to moderate VH. α mean ± SD; ** column %; Ϯ p = .006, ∆ p = .09 compared to mild VH; u p =.06; ϴ p = .04 compared to mild VH; Ɣ p = .02; β p = .02 compared to mild VH; Ω p = .08 compared to mild; ¥ p = .01 compared to moderate VH; κ p = .08 compared to moderate VH. λ p = .001 compared to mild and moderate VH. ϮϮ p = .001. π p = .03 compared to moderate VH.